Viridian Therapeutics, Inc.\DE — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+83.3% +$60K
$132K
Cost of Revenue
—
R&D↑+24.0% +$17M
$89M
D&A↓-2.4% -$3K
$120K
Operating Income↑+52.1% +$43M
$-40M
EBITDA↓-2.4% -$3K
$120K
Interest Expense↑+36366.7% +$3M
$3M
Interest Income↓-8.5% -$728K
$8M
Net Income↑+54.9% +$42M
$-35M
Operating Margin↑+97013.1pts
-56.7%
Net Margin↑+89124.2pts
-49.0%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
5.0%
Operating Lease Cost
—
Revenue YoY Variation↑+83.3pts
83.3%
Income YoY Variation↑+115.0pts
52.1%
Revenue QoQ Variation↓-83.5pts
-99.8%
Income QoQ Variation↑+78.2pts
62.5%